Astra Zeneca and Merck partner on drug regimen

The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.